investors and funds getting in before this really takes off.
Adam Feuerstein @adamfeuerstein 10m
My 2 cents: $GERN higher Mon/Tues on confirmed/solid bone marrow response + some evidence clinical benefit. No idea how much.
I just checked his twitter he is not being sarcastic, he is being serious, nice try shortie lol
FDA approval came early..no runup on this going to $80's Monday
will be even higher now
New York Times
Imbruvica, Gains F.D.A. Approval ,C.L.L. . To Follow
Published: November 14, 2013
Wall Street analysts have projected sales of several billion dollars a year for Imbruvica, which is known generically as ibrutinib. The F.D.A. had designated Imbruvica a “breakthrough therapy” for three types of cancer under a program established by Congress last year. That designation contributed to the drug’s approval more than three months before the F.D.A.’s deadline in late February.
There was some concern among investors that the drug was not approved for C.L.L. on Wednesday .Executives at Pharmacyclics and Johnson & Johnson said the F.D.A. was continuing to evaluate that application and that FDA approval on C.L.L. should be out soon.
this is cheap
Successful commercialization of Imbruvica in the MCL indication would bring in substantial revenues to Pharmacyclics. The drug is being developed to treat other cancer forms as well.
Pharmacyclics, a biopharmaceutical company, Zacks Gives a Buy Rating.